# Myelofibrosis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/myelofibrosis

> 4 upcoming FDA catalysts in myelofibrosis: elritercept (TAK) on Feb to May 2028 (topline data readout); elritercept (TAK) on February 2028 (primary completion); RYTELO (imetelstat, GERN) on Jun to Sep 2028 (topline data readout); RYTELO (imetelstat, GERN) on June 2028 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 20, 2026 | [XPOVIO® (selinexor) primary completion](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Myelofibrosis | completed | "NCT04562389 (Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04562389)) |
| August 31, 2026 | [XPOVIO® (selinexor) NDA/BLA submission](https://sec-api.dev/pdufa/selinexor) | KPTI | myelofibrosis | completed | "The Company's primary focus is on marketing XPOVIO in its currently approved indications and on developing and seeking regulatory approval of selinexor for the treatment of myelofibrosis, for which the Company submitted a supplemental New Drug Application to the FDA on August 31, 2026 seeking accelerated approval." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1503802/000119312526444164/d141618dex991.htm)) |
| September 2026 | [XPOVIO® (selinexor) primary completion](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Myelofibrosis | delayed | "NCT04562870 (A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04562870)) |
| Sep to Dec 2026 | [XPOVIO® (selinexor) topline data readout](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Myelofibrosis | scheduled | "NCT04562870 (A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04562870)) |
| Feb to May 2028 | [Elritercept topline data readout](https://sec-api.dev/pdufa/elritercept) | TAK | Myelofibrosis | scheduled | "NCT05037760 (A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05037760)) |
| February 2028 | [Elritercept primary completion](https://sec-api.dev/pdufa/elritercept) | TAK | Myelofibrosis | scheduled | "NCT05037760 (A Study of Elritercept Alone or Together With Ruxolitinib in Adults With Myelofibrosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-02-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05037760)) |
| Jun to Sep 2028 | [RYTELO (imetelstat) topline data readout](https://sec-api.dev/pdufa/imetelstat) | GERN | Myelofibrosis | scheduled | "NCT04576156 (A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Geron Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04576156)) |
| June 2028 | [RYTELO (imetelstat) primary completion](https://sec-api.dev/pdufa/imetelstat) | GERN | Myelofibrosis | scheduled | "NCT04576156 (A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-30 (ESTIMATED); Lead Sponsor Geron Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04576156)) |

## Drugs

- [XPOVIO® (selinexor)](https://sec-api.dev/pdufa/selinexor) (KPTI)
- [Elritercept](https://sec-api.dev/pdufa/elritercept) (TAK)
- [RYTELO (imetelstat)](https://sec-api.dev/pdufa/imetelstat) (GERN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/myelofibrosis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Myelofibrosis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/myelofibrosis

```bibtex
@misc{secapidev_indications_myelofibrosis_20261116,
  title        = {Myelofibrosis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/myelofibrosis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_myelofibrosis_20261116","title":"Myelofibrosis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/myelofibrosis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
